InvestorsHub Logo
Followers 138
Posts 23723
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Sunday, 12/21/2014 12:21:54 AM

Sunday, December 21, 2014 12:21:54 AM

Post# of 2207

Dr Peter French, CEO of Benitec, said, “This is a very pleasing result for Calimmune and for ddRNAi in general. It provides important early validation of the safety of this ddRNAi approach for human therapeutic applications. Cal-1 is potentially a one-shot curative approach for HIV/AIDS. This trial, along with our trial of ddRNAi for hepatitis C, demonstrates that the use of Benitec’s gene silencing technology clinically is gaining momentum. We look forward to further encouraging news as this trial proceeds.”



http://blt.live.hqi.com.au/IRM/Company/ShowPage.aspx/PDFs/1400-56170043/CALIMMUNETRIALADVANCES

Good luck and GOD bless and Merry CHRISTmas and Happy Hanukkah.

George
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BNTC News